Why Pfizer, BioNTech, and Moderna Stocks Are Getting a Bump Today

What happened

Shares of the leading COVID-19 vaccine makers received a modest bump today. Pfizer (NYSE: PFE) stock was up 1.5% as of 10:38 a.m. EDT on Friday. Shares of the company's partner, BioNTech (NASDAQ: BNTX), rose 2.2%. Moderna (NASDAQ: MRNA) stock was also up 2.1%.

There was a common catalyst for these vaccine stocks. The U.S. Food and Drug Administration announced Thursday evening that it had expanded the Emergency Use Authorizations for the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to include a third booster dose for immunocompromised individuals.

Healthcare professional giving a shot to a person.

Image source: Getty Images.

So what

The FDA specifically mentioned organ transplant recipients as being eligible for booster doses. The agency also said that individuals who are similarly immunocompromised could receive booster shots as well.

While this is good news for Pfizer, BioNTech, and Moderna, it likely won't move the needle very much in terms of sales. Acting FDA commissioner Janet Woodcock used the phrase "small, vulnerable group" to describe the individuals who would qualify for the booster doses. Most Americans won't be affected by the EUA changes.

Now what

Woodcock stated that the agency currently believes that individuals who aren't immunocompromised and are fully vaccinated "are adequately protected and do not need an additional dose of COVID-19 vaccine at this time." However, the FDA continues to review whether or not booster doses will be needed for more people in the U.S.

Even if the FDA determines that booster doses are appropriate for the larger population, it might not have a huge impact on revenue for Pfizer, BioNTech, and Moderna. The U.S. has already ordered enough doses from the companies to provide booster shots for many Americans.

10 stocks we like better than Pfizer
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 9, 2021

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.